Galectin Therapeutics

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the second $10 million convertible note pursuant to a financing agreement entered in September, 2021, with Richard E. Uihlein, the Company's Chairman and largest individual stockholder. In total, the Company has received $30 million in three convertible notes from Mr. Uihlein in 2021.

Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein

NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022

Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting

Board approves exploration of a Company-sponsored belapectin oncology program complementing our ongoing NASH cirrhosis program

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update

NORCROSS, Ga., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will present six scientific abstracts at The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held virtually from November 12 to 15, 2021.

UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

NORCROSS, Ga., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it will present six scientific abstracts at The Liver Meeting™ 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held virtually from November 12 to 15, 2021.

Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLD

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 5th Annual NASH Investor Conference being held virtually on October 12, 2021.

UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

NORCROSS, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company's management will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The virtual conference will take place from September 13–15, 2021. In addition to the presentation, management will conduct 1-on-1 meetings with investors. For more information on the conference or to register, visit: HCW Events.

Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company's management will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The virtual conference will take place from September 13–15, 2021. In addition to the presentation, management will conduct 1-on-1 meetings with investors. For more information on the conference or to register, visit: HCW Events.

Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has recently expanded its management team with multiple key leadership appointments, including Dakshina Reddy, MSM, as Executive Director, Regulatory Affairs; Ezra R. Lowe, Ph.D., as Executive Director, Clinical and Preclinical Pharmacology; Marla Mills-Wilson as Executive Director, Clinical Operations; and Jessica Kopaczewski as Associate Director, Clinical Operations. These strategic appointments strengthen the company's clinical, regulatory, and operational efforts across its ongoing programs in cancer immunotherapy and NASH cirrhosis.

Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis

Considering options for a Combination Cancer Immunotherapy trial based on encouraging results of Phase 1b trial which strengthened the rationale to conduct a larger, randomized controlled Phase 2 study Considering options for a Combination Cancer Immunotherapy trial based on encouraging results of Phase 1b trial which strengthened the rationale to conduct a larger, randomized controlled Phase 2 study

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update

The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased 25% yesterday. This is why it happened.

GALT Stock Increased 25%: Why It Happened

Today, a key announcement of some positive clinical trial data has sent investors in Galectin and GALT stock on a nice ride. The post GALT Stock: The Big Trial News That Has Galectin Therapeutics Soaring appeared first on InvestorPlace.

GALT Stock: The Big Trial News That Has Galectin Therapeutics Soaring

Sigilon Therapeutics

Galectin Therapeutics Inc. (NASDAQ: GALT) and Sigilon Therapeutics, Inc. (NASDAQ: SGTX) are among the biggest movers among biopharma stocks in early trading Friday. Galectin Spikes On Positive Data For Early-stage Cancer Study: Galectin along with partner the Earle A.

Why Galectin Is Soaring And Sigilon Is Sinking Today

Galectin Therapeutics Inc (NASDAQ: GALT) has announced top-line clinical data from the extension cohort of Phase 1b trial of Belapectin in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients with metastatic melanoma and head & neck cancer. The extension study enrolled heavily-pretreated nine melanoma patients and five head & neck squamous cell carcinoma cancer patients.

Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer

The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased by over 40% pre-market. This is why it happened.

Galectin Therapeutics Stock Increases Over 40% Pre-Market: Why It Happened

Adomani

AIM ImmunoTech Inc

Asensus Surgical

Cinedigm

Genius Brands

Luokung Technology Corp

Electrameccanica

Are these 'must watch' penny stocks on your radar? The post 8 ‘Must Watch' Penny Stocks For Your July 2021 List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

8 ‘Must Watch' Penny Stocks For Your July 2021 List

NORCROSS, Ga., July 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and the Earle A. Chiles Research Institute, a division of the Providence Cancer Institute, today announced top-line clinical data from the extension cohort of an investigator-initiated Phase 1b clinical trial of Belapectin, a galectin-3 inhibitor, in combination with KEYTRUDA® (pembrolizumab) in patients with metastatic melanoma and head and neck cancer1. The study is conducted under the direction of Dr. Brendan D. Curti, M.D., a renowned cancer and melanoma expert2.

Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer

Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update

NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer , will present the belapectin program at the 4th Global NASH Congress taking place virtually on April 28 and 29, 2021.

Galectin Therapeutics to Present at 4th Global NASH Congress

Recent immuno-oncology publications further confirm the Galectin Signature in cancer immunotherapy. In a rare and important combination of clinical effects, belapectin, Galectin's galectin-3 inhibitor, we believe can both augment ICI or immune agonist therapy while simultaneously improving toxicity/tolerability profiles.

Galectin Therapeutics: The Galectin Signature - Signed, Sealed, And About To Be Delivered

Galectin Therapeutics Inc (NASDAQ: GALT) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's belapectin in head & neck cancer, lung cancer, and melanoma. The study assessing belapectin combined with Merck's & Co's (NYSE: MRK) Keytruda (pembrolizumab) is being conducted to collaborate between Galectin and Providence Cancer Institute in Portland.

Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response

The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased by over 25% pre-market. This is why it happened.

GALT Stock: Over 25% Increase Pre-Market Explanation

Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone

Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics' Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy

The stock price of Galectin Therapeutics Inc. (NASDAQ: GALT) increased by 35.27%. This is why it happened.

Galectin Therapeutics Stock Price Increased 35.27%: Why It Happened

Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis

News for Galectin Therapeutics Stock (GALT)